Literature DB >> 9144523

Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS.

H Tomiyama1, K Miwa, H Shiga, Y I Moore, S Oka, A Iwamoto, Y Kaneko, M Takiguchi.   

Abstract

We recently showed HLA-B35-restricted CTL activity for 10 HIV-1 epitopes in PBL from two HIV-1-infected individuals. In the present study, we established CTL clones specific for nine of these HIV-1 epitopes to confirm these HLA-B35-restricted epitopes. The specific CTL clones effectively killed the HLA-B*3501-positive target cells infected with the HIV-1 vaccinia recombinant virus. These results confirmed that nine HIV-1 CTL epitopes are presented by HLA-B*3501 molecules. The CTL activity specific for four Pol and two Nef epitopes was induced in the peptide-stimulated PBL from three or more of seven HIV-1-infected individuals, indicating that these six are common epitopes. Eight were considered strong epitopes because the specific CTL activity was detected in the cultured PBL that was once stimulated with peptides. Thus, the present study excluded the possibility that the disability of the presentation of HIV-1 epitopes by HLA-B35 molecules is associated with the accelerated progression of AIDS in HLA-B35-positive individuals. Analysis of mutated epitopes found in an HIV-1 type B strain using the CTL clones revealed that most mutated epitopes partially or markedly affect the recognition of CTL clones. Of 19 mutations that affected recognition of the CTL clones, 7 reduced peptide-HLA-B*3501 binding, while 12 affected TCR recognition. These results indicate that natural mutations of HLA-B35-restricted HIV-1 CTL epitopes affect the recognition of CTL by mechanisms that reduce both peptide binding and TCR recognition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144523

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 2.  Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS.

Authors:  Koushik Chatterjee
Journal:  J Genet       Date:  2010-04       Impact factor: 1.166

3.  Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.

Authors:  Fred W Peyerl; Heidi S Bazick; Michael H Newberg; Dan H Barouch; Joseph Sodroski; Norman L Letvin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Authors:  D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.

Authors:  Nozomi Kuse; Mohammad Arif Rahman; Hayato Murakoshi; Giang Van Tran; Takayuki Chikata; Madoka Koyanagi; Kinh Van Nguyen; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

6.  Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity.

Authors:  P O Flores-Villanueva; E J Yunis; J C Delgado; E Vittinghoff; S Buchbinder; J Y Leung; A M Uglialoro; O P Clavijo; E S Rosenberg; S A Kalams; J D Braun; S L Boswell; B D Walker; A E Goldfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

7.  Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression.

Authors:  D T Evans; P Jing; T M Allen; D H O'Connor; H Horton; J E Venham; M Piekarczyk; J Dzuris; M Dykhuzen; J Mitchen; R A Rudersdorf; C D Pauza; A Sette; R E Bontrop; R DeMars; D I Watkins
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope.

Authors:  Philippa C Matthews; Madoka Koyanagi; Henrik N Kløverpris; Mikkel Harndahl; Anette Stryhn; Tomohiro Akahoshi; Hiroyuki Gatanaga; Shinichi Oka; Claudia Juarez Molina; Humberto Valenzuela Ponce; Santiago Avila Rios; David Cole; Jonathan Carlson; Rebecca P Payne; Anthony Ogwu; Alfred Bere; Thumbi Ndung'u; Kamini Gounder; Fabian Chen; Lynn Riddell; Graz Luzzi; Roger Shapiro; Christian Brander; Bruce Walker; Andrew K Sewell; Gustavo Reyes Teran; David Heckerman; Eric Hunter; Søren Buus; Masafumi Takiguchi; Philip J R Goulder
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

9.  CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Authors:  T M Allen; B R Mothé; J Sidney; P Jing; J L Dzuris; M E Liebl; T U Vogel; D H O'Connor; X Wang; M C Wussow; J A Thomson; J D Altman; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

10.  Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8(+) T-cell cytolytic activity and cytokine production.

Authors:  Hiroko Tomiyama; Hirofumi Akari; Akio Adachi; Masafumi Takiguchi
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.